• ATTO share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of ATTO shares has increased $0.27 since the market last closed. This is a 1.80% rise.

  • Closed at $15.27.

    The stock has remained unchanged in after-hours trading.

Key terms

About ATTO

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $697.09M

    A market capitalization between $300 million and $2 billion places ATTO in the small capitalization category.

Key terms

Smart score

Latest ATTO news

Oct 14, 2026 6:36am ET Attovia Therapeutics: Buy Rating Reaffirmed on Pipeline Momentum and Upcoming Catalysts, Price Target Unchanged at $30 by TipRanks Sep 04, 2026 6:30am ET Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN) by TipRanks Sep 03, 2026 11:55am ET Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway by TipRanks Sep 03, 2026 9:05am ET Morgan Stanley Gives a Buy Rating to Attovia Therapeutics, Inc. (ATTO) by TipRanks Sep 03, 2026 7:50am ET Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO) by TipRanks Sep 02, 2026 4:15pm ET Attovia reports Q2 EPS ($4.88), consensus ($4.61) by TipRanks Aug 31, 2026 9:50am ET Deere upgraded, Lumentum initiated: Wall Street’s top analyst calls by TipRanks Aug 31, 2026 6:25am ET Attovia initiated with an Outperform at LifeSci Capital by TipRanks Aug 31, 2026 6:25am ET Attovia initiated with an Outperform at Leerink by TipRanks Aug 31, 2026 5:15am ET Attovia initiated with a Buy at Citi by TipRanks Aug 31, 2026 5:10am ET Attovia initiated with an Overweight at Morgan Stanley by TipRanks Aug 31, 2026 2:25am ET Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital by TipRanks Aug 30, 2026 8:25pm ET Attovia initiated with an Outperform at RBC Capital by TipRanks Aug 10, 2026 10:11pm ET Major Investor Makes Bold Move Into Attovia Therapeutics by TipRanks Aug 10, 2026 11:20am ET Opening Day: Biotech names lead week’s IPO activity by TipRanks Aug 07, 2026 10:02pm ET Major Pharma Giant Deepens Its Bet on Attovia Therapeutics With a Fresh Multi-Million-Dollar Buy by TipRanks Aug 06, 2026 10:09pm ET Major Investor Doubles Down on Attovia Therapeutics in Bold New Move by TipRanks Aug 06, 2026 4:47pm ET Attovia adopts new charter and bylaws post-IPO by TipRanks Aug 04, 2026 8:30am ET Attovia 17M share IPO priced at $17.00 by TipRanks
Nov 05, 2026 4:05pm ET Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis by GlobeNewswire Oct 27, 2026 4:05pm ET Attovia Therapeutics to Participate in Upcoming Investor Conferences by GlobeNewswire Sep 28, 2026 4:05pm ET Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 by GlobeNewswire Sep 03, 2026 4:05pm ET Attovia Therapeutics to Participate in Upcoming Investor Conferences by GlobeNewswire Sep 02, 2026 4:05pm ET Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update by GlobeNewswire Aug 06, 2026 4:05pm ET Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Aug 06, 2026 4:05pm ET Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Aug 04, 2026 8:50pm ET Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering by GlobeNewswire

ATTO Financials

1-year income & revenue

  • ATTO total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • ATTO net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • ATTO earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

ATTO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ATTO Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    ATTO's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $697.09M

    A market capitalization between $300 million and $2 billion places ATTO in the small capitalization category.

Key terms

Latest investing news